DBV Technologies | DBVT - Operating Expenses


DBV Technologies reported $37.05M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.37M 14.6M Sep/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Galectin Therapeutics USD 11.29M 1.64M Jun/2024
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
United Therapeutics USD 6.59B 6.07B Sep/2025